Arbutus Biopharma Corporation (ABUS)

2.6800 -0.0100 (-0.37%) 收市：04:00PM EDT

Arbutus Biopharma Corporation

701 Veterans Circle
Warminster, PA 18974
United States
267 469 0914
https://www.arbutusbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 73

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Michael J. McElhaugh	Co-Founder, Interim President, CEO & Director	644.4k	無	1975
Dr. Michael J. Sofia Ph.D.	Chief Scientific Officer	656.1k	無	1958
Mr. David C. Hastings CPA	CFO & Chief Accounting Officer	647.1k	無	1961
Ms. Lisa M. Caperelli	Vice President of Investor Relations	無	無	無
Mr. J. Christopher Naftzger BA, Esq., J.D.	General Counsel, Chief Compliance Officer & Secretary	無	無	1967
Ms. Shannon Briscoe SPHR	Vice President of Human Resources	無	無	無
Dr. Karen Sims M.D., Ph.D.	Chief Medical Officer	無	無	1971
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.	Corporate Secretary	無	無	1951

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

公司管治

截至 2024年5月1日 止，Arbutus Biopharma Corporation 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：1；董事會：5；股東權利：9；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。